Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies

The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gynecological cancer Vol. 29; no. 5; pp. 956 - 968
Main Authors Hinchcliff, Emily, Westin, Shannon Neville, Dal Molin, Graziela, LaFargue, Christopher J, Coleman, Robert L
Format Journal Article
LanguageEnglish
Published England by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology 01.06.2019
BMJ Publishing Group LTD
Subjects
Apoptosis
Cancer therapies
Chemotherapy
DNA methylation
DNA repair
FDA approval
Mutation
Ovarian cancer
Response rates
Tumors
United States > US
medical oncology
ovarian cancer
Online AccessGet full text

Cover

More Information
Summary:The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributions: RC was invited to contribute review article. EH and RC were responsible for conception, writing and editing of manuscript. All authors (EH,RC, SW, GD, CJ) contributed to literature review, and all authors edited and approved final manuscript prior to submission.
ISSN:1048-891X
1525-1438
DOI:10.1136/ijgc-2019-000499